10 stories mentioning HKG:9995Updated 3d ago
Every FINWIRES story that references HKG:9995, newest first.
RemeGen (HKG:9995) has an average rating of buy and mean price target of HK$120.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
RemeGen (HKG:9995, SHA:688331) proposed to repurchase shares worth between 25 million yuan and 50 million yuan, according to a Monday disclosure on the Shanghai bourse.The company will repurchase between 167,800 and 335,600 shares at a maximum price of 149 yuan per share through centralized bidding within 12 months after approval by the board of directors.The repurchased shares will be used for the company's employee stock ownership plan or equity incentive plan.Hong Kong-listed shares of the pharmaceutical company were up 8% in Monday afternoon trading, while its Shanghai shares were up 6%.
RemeGen (HKG:9995, SHA:688331) proposed to repurchase shares worth between 25 million yuan and 50 million yuan, according to a Monday disclosure on the Shanghai bourse.Approximately between 167,800 shares and 335,600 shares will be bought for up to 149 yuan through centralized bidding within 12 months after approval by the board of directors.The repurchased shares will be used for the company's employee stock ownership plan or equity incentive plan.Hong Kong-listed shares of the pharmaceutical company were up 8% in Monday afternoon trading, while its Shanghai shares were up 6%.
RemeGen (HKG:9995, SHA:688331) obtained a drug registration certificate and conditional marketing approval for a new indication of Telitacicept Injection from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The new indication of the drug is for the treatment of IgA nephropathy, or to reduce proteinuria in adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.
RemeGen (HKG:9995, SHA:688331) obtained a drug registration certificate and marketing approval for a new indication of Telitacicept for Injection from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The new indication of the drug is for the treatment of Sjögren's syndrome, the biopharmaceutical company said.
Shanghai Junshi Biosciences (HKG:1877, SHA:688180) received a drug registration certificate from China's National Medical Products Administration for a new indication for toripalimab, according to a Hong Kong bourse filing on Thursday.The pharmaceutical company's Shanghai shares dropped by less than 4%, while Hong Kong shares fell by less than 2% during Friday's morning trade.The drug, which trades as Tuoyi, will be allowed for the treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma in combination with disitamab vedotin, an antibody drug conjugate developed by RemeGen (HKG:9995, SHA:688331).
RemeGen (HKG:9995, SHA:688331) said it invested in various wealth management products offered by Huatai Securities, according to a Friday filing with the Hong Kong bourse.The biopharmaceutical company invested 60 million yuan in a fixed-income product that invests in debt assets, 75 million yuan in another fixed-income product that covers liquid financial instrument, and a further 102 million yuan in a fixed-income product tied to financial products and cash-type assets.The company also invested 216 million yuan in a ten-year product that will be invested in financial products and cash-type assets.The firm said the products will help "revitalize idle funds."
RemeGen (HKG:9995, SHA:688331) booked 328 million yuan in attributable profit for the first quarter of 2026, swinging from a loss of 254.1 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.The biopharmaceutical company's Hong Kong shares were down 2% in late morning trade Wednesday.Earnings per share were 0.58 yuan, compared with a loss of 0.46 year in the prior year period.Operating revenue jumped 25% year on year to 656.2 million yuan, figures showed.
RemeGen (HKG:9995) said it received a $650 million upfront payment from AbbVie under a previously entered global licensing agreement involving RC148, according to a Hong Kong bourse filing Wednesday.The deal also includes milestone payments of up to $4.95 billion and tiered double-digit royalties on overseas sales.RC148 is a bispecific antibody designed to enhance anti-tumor immune responses while inhibiting tumor-driven angiogenesis.
RemeGen (HKG:9995) said China's drug regulator approved its Disitamab Vedotin for the treatment of a type of bladder cancer, according to a Hong Kong bourse filing Friday.Shares of the firm gained over 4% in morning trade Monday.The drug was approved in combination with toripalimab for the treatment of urothelial carcinoma which expresses the HER2 protein.The approval marks the fifth indication for Disitamab Vedotin in China.
